Paul J. Tiseo
Directeur Technique/Scientifique/R&D chez COGNITION THERAPEUTICS, INC.
Profil
Paul J.
Tiseo is currently the Vice President-Clinical Development at Cognition Therapeutics, Inc. Prior to this, he worked as the Executive Director-Clinical Development at Centrexion Therapeutics Corp.
He completed his undergraduate degree at Stony Brook University and his doctorate at Lewis Katz School of Medicine.
Postes actifs de Paul J. Tiseo
| Sociétés | Poste | Début |
|---|---|---|
| COGNITION THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 11/10/2022 |
Anciens postes connus de Paul J. Tiseo
| Sociétés | Poste | Fin |
|---|---|---|
| CENTREXION THERAPEUTICS CORPORATION | Corporate Officer/Principal | - |
Formation de Paul J. Tiseo
| Stony Brook University | Undergraduate Degree |
| Lewis Katz School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| COGNITION THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Centrexion Therapeutics Corp.
 Centrexion Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. Its product pipeline includes CNTX-4975, CNTX-0290, CNTX-6970, CNTX-2022, CNTX-6016, and intrathecal platform. The company was founded by Sol J. Barer and Jeffrey B. Kindler in February 2013 and is headquartered in Boston, MA. | Health Technology |